Roman Butler Fullerton & Co’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $570K | Buy |
23,293
+29
| +0.1% | +$759 | 0.14% | 167 |
|
|
2026
Q1 | $639K | Buy |
23,264
+28
| +0.1% | +$745 | 0.18% | 138 |
|
|
2025
Q4 | $606K | Sell |
23,236
-2,579
| -10% | -$65K | 0.16% | 149 |
|
|
2025
Q3 | $627K | Sell |
25,815
-2,017
| -7% | -$49.8K | 0.17% | 135 |
|
|
2025
Q2 | $690K | Sell |
27,832
-295
| -1% | -$6.88K | 0.2% | 123 |
|
|
2025
Q1 | $631K | Sell |
28,127
-11,684
| -29% | -$306K | 0.25% | 103 |
|
|
2024
Q4 | $1.07M | Buy |
39,811
+5,348
| +16% | +$145K | 0.34% | 77 |
|
|
2024
Q3 | $1.01M | Sell |
34,463
-15,915
| -32% | -$464K | 0.31% | 82 |
|
|
2024
Q2 | $1.43M | Sell |
50,378
-1,085
| -2% | -$29.9K | 0.46% | 52 |
|
|
2024
Q1 | $1.35M | Sell |
51,463
-27,271
| -35% | -$757K | 0.51% | 55 |
|
|
2023
Q4 | $2.16M | Buy |
78,734
+23,783
| +43% | +$719K | 0.84% | 29 |
|
|
2023
Q3 | $1.76M | Sell |
54,951
-3,957
| -7% | -$140K | 0.83% | 29 |
|
|
2023
Q2 | $2.15M | Sell |
58,908
-13,235
| -18% | -$515K | 0.99% | 24 |
|
|
2023
Q1 | $2.84M | Buy |
72,143
+15,985
| +28% | +$690K | 1.41% | 14 |
|
|
2022
Q4 | $2.59M | Buy |
56,158
+3,359
| +6% | +$161K | 1.34% | 15 |
|
|
2022
Q3 | $2.21M | Buy |
52,799
+2,211
| +4% | +$107K | 1.41% | 15 |
|
|
2022
Q2 | $2.62M | Sell |
50,588
-645
| -1% | -$32.9K | 1.45% | 17 |
|
|
2022
Q1 | $2.65M | Sell |
51,233
-219
| -0.4% | -$11.4K | 1.23% | 18 |
|
|
2021
Q4 | $3.04M | Sell |
51,452
-811
| -2% | -$40.2K | 1.34% | 16 |
|
|
2021
Q3 | $2.16M | Sell |
52,263
-143
| -0.3% | -$6.33K | 1.01% | 25 |
|
|
2021
Q2 | $2.05M | Buy |
52,406
+94
| +0.2% | +$3.65K | 1% | 24 |
|
|
2021
Q1 | $1.97M | Buy |
52,312
+1,366
| +3% | +$48.5K | 0.98% | 21 |
|
|
2020
Q4 | $1.88M | Sell |
50,946
-4,650
| -8% | -$171K | 1.11% | 20 |
|
|
2020
Q3 | $1.94M | Buy |
55,596
+437
| +0.8% | +$15.3K | 1.27% | 19 |
|
|
2020
Q2 | $1.71M | Sell |
55,159
-3,870
| -7% | -$131K | 1.22% | 18 |
|
|
2020
Q1 | $1.83M | Sell |
59,029
-14,357
| -20% | -$489K | 1.61% | 12 |
|
|
2019
Q4 | $2.73M | Buy |
73,386
+8,663
| +13% | +$309K | 1.8% | 10 |
|
|
2019
Q3 | $2.21M | Sell |
64,723
-2,194
| -3% | -$79.8K | 1.53% | 14 |
|
|
2019
Q2 | $2.75M | Buy |
66,917
+3,721
| +6% | +$148K | 1.85% | 11 |
|
|
2019
Q1 | $2.55M | Buy |
63,196
+13,540
| +27% | +$542K | 1.78% | 11 |
|
|
2018
Q4 | $1.99M | Buy |
+49,656
| New | +$2.06M | 1.69% | 10 |
|
Other funds holding PFE
Roman Butler Fullerton & Co's PFE Position: Q2 2026 in Review
Roman Butler Fullerton & Co increased its Pfizer (PFE) stake by 0.12% in Q2 2026, buying an estimated $759 and bringing the position to 23,293 shares worth $570K. The position accounts for 0.14% of the portfolio, ranked #167.
Roman Butler Fullerton & Co first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.04M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Roman Butler Fullerton & Co held 23,293 shares of Pfizer worth $570K as of Q2 2026.
- Roman Butler Fullerton & Co bought 29 Pfizer shares in Q2 2026, an estimated $759.
- Pfizer made up 0.14% of Roman Butler Fullerton & Co's portfolio in Q2 2026, its #167 holding.
- Roman Butler Fullerton & Co first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Roman Butler Fullerton & Co's Pfizer position peaked at $3.04M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Roman Butler Fullerton & Co's 13F filing for Q2 2026, filed 6 Aug 2026.